A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration

Biochemical and Biophysical Research Communications

Volumn 440, Issue 3, 2013, Pages 359-363

  Fujiwara, Takeshi ^a   Morimoto, Koji ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Excitotoxicity; Mitochondrial dysfunction; Neurodegeneration; P53

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; MUTANT PROTEIN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CONFORMATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EMBRYO; EXCITOTOXICITY; NERVE FIBER; NERVE FIBER DEGENERATION; NEURITE; NEUROPROTECTION; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; RAT; WILD TYPE;

4′,6′-DIAMIDINO-2-PHENYLINDOLE; AD; ALS; ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM; CNS; CP-31398; DAPI; DAYS IN VITRO; DIV; EXCITOTOXICITY; GFP; GREEN FLUORESCENT PROTEIN; MITOCHONDRIAL DYSFUNCTION; NEURODEGENERATION; N′-[2-[2-(4-METHOXYPHENYL)ETHENYL]-4-QUINAZOLINYL]-N,N-DIMETHYL-1,3-PROPANEDIAMINE DIHYDROCHLORIDE; P53; PARKINSON'S DISEASE; PD; PI; PROPIDIUM IODIDE;

ANIMALS; APOPTOSIS; AXONS; CELLS, CULTURED; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HIPPOCAMPUS; MITOCHONDRIA; NERVE DEGENERATION; OXIDOREDUCTASES; PYRIMIDINES; RATS; RATS, WISTAR;

EID: 84888134031     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.052     Document Type: Article

References (31)

1. Hilliard M.A. Axonal degeneration and regeneration: a mechanistic tug-of-war. J. Neurochem. 2009, 108:23-32.
2. Conforti L., Adalbert R., Coleman M.P. Neuronal death: where does the end begin?. Trends Neurosci. 2007, 30:159-166.
3. Libby R.T., Li Y., Savinova O.V., Barter J., Smith R.S., Nickells R.W., John S.W.M. Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet. 2005, 1:17-26.
4. Sagot Y., Duboisdauphin M., Tan S.A., Debilbao F., Aebischer P., Martinou J.C., Kato A.C. Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. J. Neurosci. 1995, 15:7727-7733.
5. Sajadi A., Schneider B.L., Aebischer P. Wld(s)-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr. Biol. 2004, 14:326-330.
6. Hasbani D.M., O'Malley K.L. Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Exp. Neurol. 2006, 202:93-99.
7. Pun S., Santos A.F., Saxena S., Xu L., Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat. Neurosci. 2006, 9:408-419.
8. Raoul C., Buhler E., Sadeghi C., Jacquier A., Aebischer P., Pettmann B., Haase G. Chronic activation in presymptornatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc. Natl. Acad. Sci. USA 2006, 103:6007-6012.
9. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers. Arch-Eur. J. Physiol. 2010, 460:525-542.
10. Tymianski M., Charlton M.P., Carlen P.L., Tator C.H. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J. Neurosci. 1993, 13:2085-2104.
11. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 2006, 5:160-170.
12. Kemp J.A., McKernan R.M. NMDA receptor pathways as drug targets. Nat. Neurosci. 2002, 5:1039-1042.
13. Johnson J.W., Kotermanski S.E. Mechanism of action of memantine. Curr. Opin. Pharmacol. 2006, 6:61-67.
14. Howard R., McShane R., Lindesay J., Ritchie C., Baldwin A., Barber R., Burns A., Dening T., Findlay D., Holmes C., Hughes A., Jacoby R., Jones R., Jones R., McKeith I., Macharouthu A., O'Brien J., Passmore P., Sheehan B., Juszczak E., Katona C., Hills R., Knapp M., Ballard C., Brown R., Banerjee S., Onions C., Griffin M., Adams J., Gray R., Johnson T., Bentham P., Phillips P. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2012, 366:893-903.
15. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286:2507-2510.
16. Takimoto R., Wang W.G., Dicker D.T., Rastinejad F., Lyssikatos J., El-Deiry W.S. The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. 2002, 1:47-55.
17. Fujiwara T., Morimoto K., Kakita A., Takahashi H. Dynein and dynactin components modulate neurodegeneration induced by excitotoxicity. J. Neurochem. 2012, 122.
18. Fujiwara T., Morimoto K. Cooperative effect of p150Glued and microtubule stabilization to suppress excitotoxicity-induced axon degeneration. Biochem. Biophys. Res. Commun. 2012, 424:82-88.
19. Fujiwara T., Morimoto K. Inhibition of p53 transactivation functionally interacts with microtubule stabilization to suppress excitotoxicity-induced axon degeneration. Biochem. Biophys. Res. Commun. 2012, 427:100-106.
20. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., Gudkov A.V. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
21. Strom E., Sathe S., Komarov P.G., Chernova O.B., Pavlovska I., Shyshynova I., Bosykh D.A., Burdelya L.G., Macklis R.M., Skaliter R., Komarova E.A., Gudkov A.V. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat. Chem. Biol. 2006, 2:474-479.
22. Luu Y., Bush J., Cheung K.J., Li G. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic bax/mitochondrial/caspase-9 pathway. Exp. Cell Res. 2002, 276:214-222.
23. Takeuchi H., Mizuno T., Zhang G.Q., Wang J.Y., Kawanokuchi J., Kuno R., Suzumura A. Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J. Biol. Chem. 2005, 280:10444-10454.
24. Wang W.G., Takimoto R., Rastinejad F., El-Deiry W.S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 2003, 23:2171-2181.
25. Demma M.J., Wong S., Maxwell E., Dasmahapatra B. CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J. Biol. Chem. 2004, 279:45887-45896.
26. Thayer S.A., Wang G.J. Glutamate-induced calcium loads: effects on energy metabolism and neuronal viability. Clin. Exp. Pharmacol. Physiol. 1995, 22:303-304.
27. Wang G.J., Thayer S.A. Sequestration of glutamate-induced Ca2+ loads by mitochondria in cultured rat hippocampal neurons. J. Neurophysiol. 1996, 76:1611-1621.
28. Wang W., Kim S.-H., El-Deiry W.S. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl. Acad. Sci. USA 2006, 103:11003-11008.
29. Tang X., Zhu Y., Han L., Kim A.L., Kopelovich L., Bickers D.R., Athar M. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J. Clin. Invest. 2007, 117:3753-3764.
30. Morrison R.S., Wenzel H.J., Kinoshita Y., Robbins C.A., Donehower L.A., Schwartzkroin P.A. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J. Neurosci. 1996, 16:1337-1345.
31. Xiang H., Hochman D.W., Saya H., Fujiwara T., Schwartzkroin P.A., Morrison R.S. Evidence for p53-mediated modulation of neuronal viability. J. Neurosci. 1996, 16:6753-6765.